CLINICAL TRIALS PROFILE FOR THORAZINE

All Clinical Trials for THORAZINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01231074 ↗	Reducing Antipsychotic-Induced Weight Gain in Children With Metformin	Completed	Nationwide Children's Hospital	Phase 1	2010-02-01	Recent but limited short term studies have shown that Metformin can slow down weight gain in obese children and in children with psychotropic-induced weight gain, two distinct pediatric populations that are at risk for obesity related co-morbid conditions. The purpose of this study is to conduct a long term prospective pilot cohort study to investigate the use of Metformin to prevent or decrease weight gain in two cohorts of children: 1) children with psychotropic induced weight gain on Metformin and 2) children with BMI above the 95th percentile on Metformin. Both study populations will be enrolled in a lifestyle weight management program
NCT03021486 ↗	Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 2/Phase 3	2017-06-05	This randomized phase II/III trial studies how well haloperidol with or without chlorpromazine works in treating delirium in patients with cancer that has spread to other parts of the body or has come back. Haloperidol and chlorpromazine may control the symptoms of delirium (loss of contact with reality) in patients with cancer.
NCT03021486 ↗	Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer	Active, not recruiting	National Institute of Nursing Research (NINR)	Phase 2/Phase 3	2017-06-05	This randomized phase II/III trial studies how well haloperidol with or without chlorpromazine works in treating delirium in patients with cancer that has spread to other parts of the body or has come back. Haloperidol and chlorpromazine may control the symptoms of delirium (loss of contact with reality) in patients with cancer.
NCT03021486 ↗	Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer	Active, not recruiting	National Institutes of Health (NIH)	Phase 2/Phase 3	2017-06-05	This randomized phase II/III trial studies how well haloperidol with or without chlorpromazine works in treating delirium in patients with cancer that has spread to other parts of the body or has come back. Haloperidol and chlorpromazine may control the symptoms of delirium (loss of contact with reality) in patients with cancer.
NCT03021486 ↗	Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer	Active, not recruiting	M.D. Anderson Cancer Center	Phase 2/Phase 3	2017-06-05	This randomized phase II/III trial studies how well haloperidol with or without chlorpromazine works in treating delirium in patients with cancer that has spread to other parts of the body or has come back. Haloperidol and chlorpromazine may control the symptoms of delirium (loss of contact with reality) in patients with cancer.

Clinical Trial Conditions for THORAZINE

Condition Name

Condition Name for THORAZINE
Intervention	Trials
Glioblastoma Multiforme	2
Locally Advanced Malignant Neoplasm	1
Malignant Neoplasms of Independent (Primary) Multiple Sites	1
Metastatic Malignant Neoplasm	1

Condition MeSH

Condition MeSH for THORAZINE
Intervention	Trials
Glioblastoma	2
Weight Gain	1
Body Weight	1
Recurrence	1

Clinical Trial Locations for THORAZINE

Trials by Country

Trials by Country for THORAZINE
Location	Trials
United States	3
Italy	3

Trials by US State

Trials by US State for THORAZINE
Location	Trials
Iowa	1
Texas	1
Ohio	1

Clinical Trial Progress for THORAZINE

Clinical Trial Phase

Clinical Trial Phase for THORAZINE
Clinical Trial Phase	Trials
Phase 2/Phase 3	1
Phase 2	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for THORAZINE
Clinical Trial Phase	Trials
Completed	1
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for THORAZINE

Sponsor Name

Sponsor Name for THORAZINE
Sponsor	Trials
Varun Monga, MD	1
Nationwide Children's Hospital	1
National Cancer Institute (NCI)	1

Sponsor Type

Sponsor Type for THORAZINE
Sponsor	Trials
Other	7
NIH	3

THORAZINE (Chlorpromazine): Clinical Trials Update and Market Outlook

Last updated: May 4, 2026

What is THORAZINE and what is the commercial positioning?

THORAZINE is the brand name for chlorpromazine, a first-generation (typical) antipsychotic used for multiple indications, including schizophrenia, manic episodes, and other psychiatric and behavioral conditions (depending on local labeling and medical practice). As an older, widely used molecule, THORAZINE’s market trajectory is driven less by near-term patent-fueled expansion and more by formulary inclusion, generic substitution dynamics, hospital purchasing patterns, and specialty demand.

Baseline commercial reality: chlorpromazine is extensively marketed as generics in many markets; brand-specific performance generally tracks (i) remaining branded inventory strategies, (ii) managed-care contracting, and (iii) supply continuity and dosage form availability rather than novel life-cycle protections.

What clinical trials exist for chlorpromazine (THORAZINE) and what is the near-term trial signal?

A “clinical trials update” for THORAZINE requires two layers of truth: (1) trials involving the active ingredient chlorpromazine and (2) whether those trials are specifically sponsored for the brand THORAZINE (vs. generic chlorpromazine). For a full update with structured endpoints, phase, enrollment, and timelines, the authoritative source is registries such as ClinicalTrials.gov and related regional registries, with sponsor-level identifiers and trial-status tracking.

No complete, registry-grounded trial dataset is available in the provided input, so a definitive trial-status table (phase-by-phase, NCT-level, recruitment status, primary endpoints, start/completion dates) cannot be produced without introducing inaccuracies.

What does the market analysis indicate for chlorpromazine/THORAZINE?

Market analysis for THORAZINE is best modeled as a mature, off-patent, competitive generic market with brand-specific constraints. The drivers are:

1. Generic penetration: chlorpromazine’s long patent history and broad generic availability compress pricing and shift volume to lowest-cost suppliers, except where branded supply or contracting preferences persist.
2. Dose-form supply and switching costs: hospitals may keep standardized antipsychotic order sets. Switching from brand to generic can occur, but it is constrained by pharmacy formularies and clinician habituation.
3. Indication stability: demand persists because chlorpromazine remains a clinically used option across certain psychiatric and behavioral indications and, in some settings, for acute agitation protocols.

Market projection approach (how to forecast in a mature generic class)

For a mature, off-patent antipsychotic, a forward-looking projection typically decomposes into:

• Total addressable treatment volume (number of treated patients and dosing frequency)
• Share shift among suppliers (generic price compression, contracted share, tender outcomes)
• Brand survival curve (if any) based on contracting and supply continuity

Because THORAZINE is an established molecule with pervasive generic competition, a realistic projection normally trends toward low single-digit CAGR or flat-to-declining branded revenue, while the overall class may grow slowly with population and diagnostic demand shifts.

However, numeric market forecasts require a market sizing baseline (current global or US units and revenue for chlorpromazine or THORAZINE), plus assumptions tied to registry-driven lifecycle events and payer contracting. No such baseline figures or region scope are provided in the input, so producing quantified projections would be unsourced.

What are the key regulatory and label dynamics to watch?

Chlorpromazine’s market access is impacted by:

• Label wording and indication scope by jurisdiction
• Safety communications and post-marketing requirements
• Formulary restrictions driven by adverse event monitoring practices

For THORAZINE-specific changes, the controlling documents are product labels and regulator communications (FDA label histories and equivalent EMA/other jurisdictions). Without jurisdiction and label revision data in the provided input, this section cannot be populated with verifiable dates and claims.

What actionable investment or R&D signals apply to chlorpromazine/THORAZINE?

Given the molecule is established, the highest-value opportunities usually sit in:

• Formulation or route optimization (if any sponsor runs active development)
• New clinical use-cases (repurposing) where trial endpoints could generate new label expansions
• Subgroup or combination strategies in settings where typical antipsychotics are used as comparators

A chlorpromazine “clinical trials update” that can drive R&D decisions must show whether current trials are:

• Recruiting vs. completed
• Enrollment size sufficient for signal detection
• Using chlorpromazine as an investigational product rather than as a background comparator

Those specifics cannot be produced from the provided input.

Key Takeaways

• THORAZINE (chlorpromazine) is a mature, off-patent antipsychotic where market performance is dominated by generic competition and formulary contracting rather than near-term patent-driven expansion.
• A registry-accurate clinical trials update with phase, endpoints, and status cannot be constructed from the provided input without risking incorrect trial mapping.
• Quantified market projections require a defined geography, baseline revenue or unit volumes, and assumptions tied to contracting and trial-driven lifecycle events; those inputs are not present here.

FAQs

1. Is THORAZINE still marketed in most regions as a brand?
   It can be marketed as a brand in some markets, but overall chlorpromazine demand is largely served by generics in many geographies.

2. Are there ongoing clinical trials for chlorpromazine that could change its label?
   Potentially, but a confirmed update requires a registry-linked trial list with current status and sponsor-level details.

3. What typically drives branded chlorpromazine revenue versus generic volume?
   Formulary placement, tender contracting, supply reliability, and maintained branded inventory strategies.

4. What R&D strategy is most realistic for chlorpromazine at this stage?
   Repurposing trials and formulation/route improvements, assuming they can create label-relevant differentiation.

5. How should an analyst project market growth for an off-patent antipsychotic?
   Use treated-volume trends and share-shift dynamics among suppliers, then apply a branded survival or contracting adjustment.

---

References

[1] ClinicalTrials.gov. (n.d.). Chlorpromazine search results and trial records. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. (n.d.). Drug label information for chlorpromazine/THORAZINE (as applicable). https://www.accessdata.fda.gov/scripts/cder/daf/